This antibody directed to the antigen CD20. The mAb is useful for inhibiting the growth of cells that express CD20.
Figure 1 The results of CellTiterGlo cell viability assays without cross-linking of Ramos cells incubated with mAbs 1.1.2, 1.2.1, 1.3.3, 1.4.3, 1.5.3, 1.6.2 and the Rituxan® (“Rituximab”) antibody control.
Percent viability of Ramos cells is shown on the y-axis and antibody concentration is shown on the x-axis.
Figure 2 The results of Alamar Blue cell viability assays without crosslinker of Ramos cells incubated with mAbs 1.6.2, 1.5.3, 1.4.3, (FIG. A) 1.3.3, 1.1.2, B1 (FIG. B) Rituximab, IgM and IgG1.
% viability is shown on the y-axis and antibody concentration is shown on the x-axis.
Figure 3 A bar graph showing the results of whole blood assays of Raji, Ramos, and Daudi cells incubated with mAbs 1.1.2, 2.1.2, Rituximab, and IgG1 control using Whole Blood assays.
Percent lysis is shown on the y-axis and Raji, Ramos, and Daudi cell lines, respectively, are shown on the x-axis. The results demonstrate mAbs 1.1.2 and 2.1.2 mediate greater cell lysis as compared to Rituximab.
Figure 4 A scatterplot showing the results of a whole blood assay comparison of lytic activity using mAbs 1.5.3, 1.1.2, and Rituximab in a panel of cell lines.
Each symbol represents a human donor of whole blood. Percent lysis at 10 μg/ml is shown on the y-axis and the ARH-77, Daudi, EHEB, JMV2, MV3, Karpas422, Namalwa, Raji, Ramos, SC1, SU-DHL-4, and WSU-NHL cell lines, respectively, are shown on the x-axis.
Figure 5 A bar graph showing lysis of Rituximab-resistant cells RR1-Raji in a whole blood assay by Rituximab, mAb 1.1.2, and mAb 1.5.3.
The percentage lysis is shown on the y-axis and and Raji parental cells treated at a concentration of antibody of 1 μg/ml and 10 μg/ml, respectively and RR1-Raji cells treated at a concentration of antibody of 1 μg/ml and 10 μg/ml, respectively, are shown on the x-axis.
Figure 6 A line graph showing the effect of anti-CD20 antibodies, Rituximab, 2.1.2, 1.1.2, and 1.5.3 on mouse survival in a Ramos i.v. paralysis model (CB17 SCID).
The results show that three anti-CD20 antibodies demonstrate potent anti-lymphoma activity when administered as a single dose monotherapy. The number of days of treatment post tumor cell implantation is shown on the x-axis and percent survival is shown on the y-axis.
Figure 1 shows the results of cell viability assays without cross-linking of Ramos cells incubated with the antibody, and the Rituxan® ("Rituximab") antibody control.
Percent viability of Ramos cells is shown on the y-axis and antibody concentration is shown on the x-axis.
Figure 2 shows the results of Annexin V/PI apoptosis assays without cross-linker of Ramos cells incubated with mAbs.
Rituximab and Bl. % viability is shown on the y-axis and antibody concentration is on the x-axis.
Figure 3 shows the results of CDC assays of Ramos cell lines, respectively, incubated with mAbs.
Figure 4 is a graph shows results of an ADCC assay of Ramos cell line incubated with mAbs 2.1.2, 1.1-2, 1.5.3, 1.10.3.1, and 1.11.3.1, Rituximab, and IgGl control. % viability is showsn on the y-axis and antibody concentration is showsn on the x-axis.
Figure 5 is a line graph shows the effect of anti-CD20 antibodies, Rituximab, 2.1.2, 1.1.2, and 1.5.3 on mouse survival in a Ramos i.v. paralysis model (CB 17 SCID).
The results show that three anti-CD20 antibodies demonstrate potent anti- lymphoma activity when administered as a single dose monotherapy. The number of days of treatment post tumor cell implantation is shown on the x-axis and percent survival is shown on the y-axis.
Figure 6 is a line graph shows the efficacy of anti-CD20 antibodies in the Daudi subcutaneous tumor model.
The number of days of treatment after the time of tumor cell inoculation is shown on the x-axis and tumor volume in cubic millimeters is shown on the y-axis.
This is a product of Creative Biolabs' Hi-Affi™ recombinant antibody portfolio, which has several benefits including:
• Increased sensitivity
• Confirmed specificity
• High repeatability
• Excellent batch-to-batch consistency
• Sustainable supply
• Animal-free production
See more details about Hi-Affi™ recombinant antibody benefits.
Download resources about recombinant antibody development and antibody engineering to boost your research.
CAT | Product Name | Application | Type |
---|---|---|---|
TAB-H27 | Anti-Human MS4A1 Recombinant Antibody (Epitumomab) | IP, IF, FuncS, FC, Neut, ELISA, ICC | IgG2a |
TAB-H39 | Anti-Human MS4A1 Recombinant Antibody (Ibritumomab) | FC, IP, ELISA, Neut, FuncS, IF, ICC | Mouse IgG1 - kappa |
TAB-1632CL-S(P) | Anti-Human MS4A1 Recombinant Antibody scFv Fragment (1F5) | FC | |
TAB-1701CL-S(P) | Mouse Anti-MS4A1 Recombinant Antibody; scFv Fragment (TAB-1701CL-S(P)) | FuncS | Mouse scFv |
TAB-007ML | Anti-Canine MS4A1 Recombinant Antibody (Blontuvetmab) | ELISA, IHC, FC, IP, IF, FuncS | IgG2, κ, λ |
CAT | Product Name | Application | Type |
---|---|---|---|
PSBW-019 | Mouse Anti-MS4A1 Recombinant Antibody (clone C2H7); scFv Fragment | WB, IF, FuncS | Mouse scFv |
HPAB-J0043-YC-S(P) | Mouse Anti-MS4A1 Recombinant Antibody (clone 13.6E12); scFv Fragment | ELISA, FC, FuncS | Mouse scFv |
HPAB-0528-YJ-S(P) | Mouse Anti-MS4A1 Recombinant Antibody (clone 2F4); scFv Fragment | ELISA, IHC | Mouse scFv |
HPAB-0529-YJ-S(P) | Mouse Anti-MS4A1 Recombinant Antibody (clone ch2F4); scFv Fragment | ELISA, IHC | Mouse scFv |
HPAB-1885-FY-F(E) | Human Anti-MS4A1 Recombinant Antibody; Fab Fragment (HPAB-1885-FY-F(E)) | ELISA, FC | Human Fab |
CAT | Product Name | Application | Type |
---|---|---|---|
TAB-0001CL | Human Anti-MS4A1 Recombinant Antibody (TAB-0001CL) | ELISA, ADCC, CDC | Human IgG |
TAB-1648CL-F(E) | Anti-MS4A1 Recombinant Antibody Fab Fragment (MEDI-552) | Inhib | |
TAB-1654CL-F(E) | Human Anti-MS4A1 Recombinant Antibody; Fab Fragment (TAB-1654CL-F(E)) | FC, Apop | Human Fab |
TAB-1655CL-F(E) | Human Anti-MS4A1 Recombinant Antibody; Fab Fragment (TAB-1655CL-F(E)) | ELISA | Human Fab |
PABX-028-F (E) | Recombinant Human Anti-CD20 Antibody Fab Fragment (Ofatumumab) | WB, ELISA, IF, FuncS | Fab |
CAT | Product Name | Application | Type |
---|---|---|---|
TAB-1638CL | Human Anti-MS4A1 Recombinant Antibody (TAB-1638CL) | ADCC, CDC | Humanized IgG |
TAB-1639CL | Human Anti-MS4A1 Recombinant Antibody (TAB-1639CL) | ADCC, CDC, Apop | Humanized IgG |
TAB-1640CL | Human Anti-MS4A1 Recombinant Antibody (TAB-1640CL) | ADCC, CDC, Apop, FuncS | Humanized IgG |
TAB-1641CL | Human Anti-MS4A1 Recombinant Antibody (TAB-1641CL) | ADCC, CDC, Apop | Humanized IgG |
TAB-1642CL | Human Anti-MS4A1 Recombinant Antibody (TAB-1642CL) | ADCC, CDC | Humanized IgG |
CAT | Product Name | Application | Type |
---|---|---|---|
TAB-1665CL-S(P) | Mouse Anti-MS4A1 Recombinant Antibody; scFv Fragment (TAB-1665CL-S(P)) | CDC | Mouse scFv |
TAB-1666CL-S(P) | Mouse Anti-MS4A1 Recombinant Antibody; scFv Fragment (TAB-1666CL-S(P)) | CDC | Mouse scFv |
TAB-1667CL-S(P) | Mouse Anti-MS4A1 Recombinant Antibody; scFv Fragment (TAB-1667CL-S(P)) | CDC | Mouse scFv |
TAB-1668CL-S(P) | Mouse Anti-MS4A1 Recombinant Antibody; scFv Fragment (TAB-1668CL-S(P)) | CDC | Mouse scFv |
TAB-1669CL-S(P) | Mouse Anti-MS4A1 Recombinant Antibody; scFv Fragment (TAB-1669CL-S(P)) | CDC | Mouse scFv |
CAT | Product Name | Application | Type |
---|---|---|---|
Gly-059LC | Recombinant Anti-Human MS4A1 Antibody (Fc glycosylation) | ELISA | Chimeric antibody (mouse/human) |
Gly-060LC | Recombinant Anti-Human MS4A1 Antibody (Fc glycosylation) | ELISA | Humanized antibody |
Gly-063LC | Recombinant Anti-Human MS4A1 Antibody (Fc glycosylation/Non fucosylated) | ELISA | Chimeric antibody (mouse/human) |
Gly-067LC | Recombinant Anti-Human MS4A1 Antibody (Fc glycosylation) | ELISA, FC | Chimeric antibody (mouse/human) |
Gly-097LC | Recombinant Anti-Human MS4A1 Antibody (Fc glycosylation) | ELISA | Chimeric antibody (mouse/human) |
CAT | Product Name | Application | Type |
---|---|---|---|
Gly-134LC-1 | Recombinant Anti-Human MS4A1 Antibody (Fc glycosylation/Non fucosylated) | ELISA | Humanized antibody |
Gly-135LC-1 | Recombinant Anti-Human MS4A1 Antibody (Fc glycosylation/Non fucosylated) | ELISA | Humanized antibody |
Gly-136LC-1 | Recombinant Anti-Human MS4A1 Antibody (Fc glycosylation/Non fucosylated) | ELISA | Humanized antibody |
Gly-137LC-1 | Recombinant Anti-Human MS4A1 Antibody (Fc glycosylation/Non fucosylated) | ELISA | Humanized antibody |
Gly-138LC-1 | Recombinant Anti-Human MS4A1 Antibody (Fc glycosylation/Non fucosylated) | ELISA | Humanized antibody |
CAT | Product Name | Application | Type |
---|---|---|---|
Gly-142LC-1 | Recombinant Anti-Human MS4A1 Antibody (Fc glycosylation/Hyper-galactosylated) | ELISA | Human antibody |
CAT | Product Name | Application | Type |
---|---|---|---|
Gly-155LC-1 | Recombinant Anti-Human MS4A1 Antibody (Fc glycosylation/High-mannose glycosylated) | ELISA | Humanized antibody |
CAT | Product Name | Application | Type |
---|---|---|---|
Gly-171LC | Recombinant Anti-Human MS4A1 Antibody (Non-glycosylated) | ELISA | Chimeric antibody (mouse/human) |
CAT | Product Name | Application | Type |
---|---|---|---|
MHC-LC066 | PE-A*02:01/Human CD20 (SLFLGILSV) MHC Tetramer | FCM | |
MHC-LC067 | APC-A*02:01/Human CD20 (SLFLGILSV) MHC Tetramer | FCM | |
MHC-LC068 | BV421-A*02:01/Human CD20 (SLFLGILSV) MHC Tetramer | FCM | |
MHC-LC4347 | PE-B*07:02/Human MS4A1 (RPKSNIVLL) MHC Tetramer | FCM |
CAT | Product Name | Application | Type |
---|---|---|---|
NEUT-1751CQ | Mouse Anti-MS4A1 Recombinant Antibody (clone CBLS-211) | Neut, FuncS | Mouse IgG1, κ |
CAT | Product Name | Application | Type |
---|---|---|---|
MOR-2295 | Hi-Affi™ Rabbit Anti-MS4A1 Recombinant Antibody (clone DS2295AB) | IHC-Fr, IHC-P | Rabbit IgG |
MOR-4024 | Hi-Affi™ Rabbit Anti-MS4A1 Recombinant Antibody (clone SI88DS) | FC | Rabbit IgG |
CAT | Product Name | Application | Type |
---|---|---|---|
FAMAB-0241CQ | Mouse Anti-MS4A1 Recombinant Antibody (clone 2H7) | ELISA, FC, IHC, IP | Mouse IgG2b, κ |
HPAB-M0452-YC | Canine Anti-MS4A1 Recombinant Antibody (HPAB-M0452-YC) | FC, IHC | Chimeric (human/canine) IgG1 |
HPAB-M0453-YC | Human Anti-MS4A1 Recombinant Antibody (HPAB-M0453-YC) | FC, IHC | Humanized IgGc |
FN-180CQ | Rat Anti-MS4A1 Recombinant Antibody (clone AISB12) | FuncS, WB, IF | Rat IgG2a |
HPAB-0346-WJ | Human Anti-MS4A1 Recombinant Antibody (clone 7F2) | ELISA | Humanized IgG |
CAT | Product Name | Application | Type |
---|---|---|---|
HPAB-0683-CN-F(E) | Human Anti-MS4A1 Recombinant Antibody (clone Rmut8); Fab Fragment | ELISA, FC | Chimeric (mouse/human) Fab |
HPAB-0684-CN-F(E) | Human Anti-MS4A1 Recombinant Antibody (clone Rmut5); Fab Fragment | ELISA, FC | Chimeric (mouse/human) Fab |
HPAB-0742-CN-F(E) | Human Anti-MS4A1 Recombinant Antibody; Fab Fragment (HPAB-0742-CN-F(E)) | ELISA, FC | Human Fab |
HPAB-0743-CN-F(E) | Human Anti-MS4A1 Recombinant Antibody; Fab Fragment (HPAB-0743-CN-F(E)) | ELISA, FC | Human Fab |
HPAB-0261CQ-F(E) | Mouse Anti-MS4A1 Recombinant Antibody (clone CBM502); Fab Fragment | ELISA, FC, FuncS | Mouse Fab |
CAT | Product Name | Application | Type |
---|---|---|---|
HPAB-M0704-YC | Camelid Anti-MS4A1 Recombinant Antibody (clone 2HCD25) | ELISA, FuncS | Camelid VHH |
HPAB-M0705-YC | Camelid Anti-MS4A1 Recombinant Antibody (clone 2HCD16) | ELISA | Camelid VHH |
HPAB-M0706-YC | Camelid Anti-MS4A1 Recombinant Antibody (clone R3CD7) | ELISA | Camelid VHH |
HPAB-M0707-YC | Camelid Anti-MS4A1 Recombinant Antibody (clone 2HCD78) | ELISA | Camelid VHH |
HPAB-M0708-YC | Camelid Anti-MS4A1 Recombinant Antibody (clone 2HCD17) | ELISA | Camelid VHH |
CAT | Product Name | Application | Type |
---|---|---|---|
AFC-TAB-772 | Afuco™ Anti-MS4A1 ADCC Recombinant Antibody (Ocrelizumab), ADCC Enhanced | ELISA, IP, FC, FuncS, Neut, IF | ADCC enhanced antibody |
AFC-TAB-016 | Afuco™ Anti-MS4A1 ADCC Recombinant Antibody (Rituximab), ADCC Enhanced | IF, IP, Neut, FuncS, ELISA, FC | ADCC enhanced antibody |
AFC-TAB-028 | Afuco™ Anti-MS4A1 ADCC Recombinant Antibody (Ofatumumab), ADCC Enhanced | FC, IP, ELISA, Neut, FuncS, IF | ADCC enhanced antibody |
AFC-TAB-207 | Afuco™ Anti-MS4A1 ADCC Recombinant Antibody (Ublituximab), ADCC Enhanced | ELISA, IP, FC, FuncS, Neut, IF | ADCC enhanced antibody |
AFC-TAB-771 | Afuco™ Anti-MS4A1 ADCC Recombinant Antibody (Ocaratuzumab), ADCC Enhanced | IF, IP, Neut, FuncS, ELISA, FC | ADCC enhanced antibody |
There are currently no Customer reviews or questions for TAB-1646CL. Click the button above to contact us or submit your feedback about this product.
View the frequently asked questions answered by Creative Biolabs Support.
For Research Use Only. Not For Clinical Use.
For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.